. . . . . . . . . "pomalyst is a thalidomide analogue indicated in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy 1 1 pomalyst in combination with dexamethasone is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "eexbn+e6FdL1dTmywQbI2yGrIwH4DENS8j594/Rnj4wpiyXTe/5/DiZgSgbqUvG9ae0AUG+wyAXgCC/sdzuxGrDTFJa8ZlRVgjOKB5dGTE9P/TJYiMEyWZ3dlAxxlCX0hurwxRu/l+yfzWxikNx/Mp6Eq7/nxfHUgR6b9UHf/JM=" . . "2021-06-12T14:48:20.601+02:00"^^ . . . . .